Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Azintuxizumab

Catalog No. T82927 Copy Product Info
Purity: 95%
🥰Excellent
Azintuxizumab, an IgG4 bispecific antibody, is designed to specifically recognize and bind to the B-cell maturation antigen (BCMA), a molecular marker associated with plasma cell malignancies. Azintuxizumab shows significant promise in preclinical and translational research investigating therapeutic interventions for relapsed or refractory multiple myeloma (RRMM), thereby providing a dual-targeted mechanism of action for antibody-based immunotherapy.

Azintuxizumab

Copy Product Info
🥰Excellent
Catalog No. T82927

Azintuxizumab, an IgG4 bispecific antibody, is designed to specifically recognize and bind to the B-cell maturation antigen (BCMA), a molecular marker associated with plasma cell malignancies. Azintuxizumab shows significant promise in preclinical and translational research investigating therapeutic interventions for relapsed or refractory multiple myeloma (RRMM), thereby providing a dual-targeted mechanism of action for antibody-based immunotherapy.

Azintuxizumab
Cas No. 1826819-57-1
TargetMol | Customer service
Customer service consultation
Pack SizePriceUSA StockGlobal StockQuantity
1 mg$247-In Stock
5 mg$747-In Stock
10 mg$1,200-In Stock
25 mg$1,770-In Stock
50 mg$2,380-In Stock
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:98.3% (SDS-PAGE); 96.8% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information

Product Introduction

Bioactivity
Description
Azintuxizumab, an IgG4 bispecific antibody, is designed to specifically recognize and bind to the B-cell maturation antigen (BCMA), a molecular marker associated with plasma cell malignancies. Azintuxizumab shows significant promise in preclinical and translational research investigating therapeutic interventions for relapsed or refractory multiple myeloma (RRMM), thereby providing a dual-targeted mechanism of action for antibody-based immunotherapy.
Reactivity
Human
Application
Functional assay
Antibody Type
Monoclonal
FormulationSupplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition.
Endotoxin<1.0 EU/mg
Related Conjugates and Formulations
Conjucates
Unconjugated
Antigen Details
Gene ID
Uniprot ID
TargetSLAMF7/CS1
Chemical Properties
Molecular Weight146.04 kDa
Cas No.1826819-57-1
Antibody Information
IsotypeHuman IgG1 kappa
Recommended Isotype Control
Storage & Solubility Information
StorageStore at -20°C Shipping with blue ice/Shipping at ambient temperature.

Citations

Calculator

  • Dilution Calculator
  • Reconstitution Calculator

Keywords

Related Tags: buy Azintuxizumab | purchase Azintuxizumab | Azintuxizumab cost | order Azintuxizumab | Azintuxizumab molecular weight